期刊
NATURE BIOMEDICAL ENGINEERING
卷 4, 期 1, 页码 125-130出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41551-019-0357-8
关键词
-
资金
- NCI NIH HHS [F31 CA224800, T32 CA203702, K22 CA181280, R01 CA195787, P30 CA014051] Funding Source: Medline
- NHGRI NIH HHS [RM1 HG009490] Funding Source: Medline
- NHLBI NIH HHS [DP2 HL137167, UG3 HL147367, P01 HL131471] Funding Source: Medline
- NIAID NIH HHS [U01 AI142756] Funding Source: Medline
- NIBIB NIH HHS [R01 EB022376] Funding Source: Medline
- NIGMS NIH HHS [R35 GM118062, T32 GM095450] Funding Source: Medline
Intravenous delivery of an adenine base editor and a single-guide RNA for the Fah gene can correct an A>G splice-site mutation in an adult mouse model of tyrosinaemia. In contrast to traditional CRISPR-Cas9 homology-directed repair, base editing can correct point mutations without supplying a DNA-repair template. Here we show in a mouse model of tyrosinaemia that hydrodynamic tail-vein injection of plasmid DNA encoding the adenine base editor (ABE) and a single-guide RNA (sgRNA) can correct an A>G splice-site mutation. ABE treatment partially restored splicing, generated fumarylacetoacetate hydrolase (FAH)-positive hepatocytes in the liver, and rescued weight loss in mice. We also generated FAH(+) hepatocytes in the liver via lipid-nanoparticle-mediated delivery of a chemically modified sgRNA and an mRNA of a codon-optimized base editor that displayed higher base-editing efficiency than the standard ABEs. Our findings suggest that adenine base editing can be used for the correction of genetic diseases in adult animals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据